The identification and molecular profiling of early metastases remains a major challenge in cancer diagnostics and therapy. Most in vivo imaging methods fail to detect small cancerous lesions, a problem that is compounded by the distinct physical and biological barriers associated with different metastatic niches. Here, we show that intravenously injected rare-earth-doped albumin-encapsulated nanoparticles emitting short-wave infrared light (SWIR) can detect targeted metastatic lesions in vivo, allowing for the longitudinal tracking of multi-organ metastases. In a murine model of human breast cancer, the nanoprobes enabled whole-body SWIR detection of adrenal-gland microlesions and bone lesions that were undetectable via contrastenhanced magnetic resonance imaging as early as three and five weeks post-inoculation, respectively. Whole-body SWIR imaging of nanoprobes functionalized to differentially target distinct metastatic sites and administered to a biomimetic murine model of human breast cancer resolved multi-organ metastases that showed varied molecular profiles in the lungs, adrenal glands and bones. Real-time surveillance of lesions in multiple organs should facilitate pre-and post-therapy monitoring in preclinical settings.
M etastasis is the primary cause of breast cancer deaths 1,2 , where the median survival rate for patients with multiorgan metastases is less than two years 1 . At present, about 10% of clinical cases present distal metastatic disease at diagnosis, and 20-40% develop distal metastasis within five years 3, 4 . The bones remain the most common site of distant metastasis in breast cancer, accounting for about 70% of diagnosed cases 5, 6 followed by the liver, lungs, adrenal glands and brain. To improve patient prognosis and survival rate, robust surveillance techniques and lesion site-specific therapies are needed. Here, we report an integrated cancer-surveillance system based on the design of nanoscale photonic probes for differential accumulation at distinct metastatic sites, coupled with deep-tissue optical detection of emergent lesions (Fig. 1 ). We demonstrate the efficacy of this approach by longitudinal surveillance of multi-organ metastatic signatures in biomimetic metastatic murine models 7, 8 .
The detection of early, multi-organ cancer metastasis is a significant challenge because distinct sites rely on unique mechanisms of microcirculation. The functional design of nanoscale probes to detect metastases needs to account for differences in the infiltration barriers and microenvironment of individual target sites. For instance, passive nanoparticle targeting to a distant site such as the bone marrow exploits the discontinuous fenestrated sinusoid capillaries and an almost absent basement membrane to increase nanoparticle infiltration 9 . In contrast, other distal sites such as the adrenal glands are not permissive to passive nanoparticle infiltration due to their continuously fenestrated sinusoid capillaries and a tight basement membrane. In this case, active functionalization of nanoparticles is necessary to achieve targeted delivery to the metastatic niche 10 . In this study, we tailored the physiochemical properties of nanoparticle formulations based on published 11, 12 tumour and distal organ pathophysiology for site-specific accumulation and simultaneous detection of multi-organ metastasis, specifically to the bone, lungs and the adrenal glands 11, 12 .
New classes of optical imaging agents that exhibit improved tissue transmittance and deep tissue penetration 13, 14 are candidates for imaging micro-metastases. We designed imaging probes based on rare-earth albumin nanocomposites (ReANCs), which are ceramic rare-earth (Re)-doped particles encapsulated in human serum albumin. These probes emit short-wave infrared (SWIR) light 15 , which has several advantageous properties for biological imaging 16, 17 . The lack of excitation− emission band overlap and elimination of tissue autofluorescence produces significantly improved signal-to-noise ratios 15 , while the narrow emission bands of the rare earths allow for multiplexed labelling. In this study, we exploit the optical emissions of ReANC probes in the SWIR (or near-infrared II) window 18 (900-1,700 nm), which is characterized by deep penetration through tissue 19 and reduced loss of spatial resolution due to scattering.
We initially sought to resolve micro-metastatic bone lesions in vivo in a biomimetic model of basal breast cancer by intravenous administration of ReANC probes. The goal was to demonstrate that SWIR-based surveillance is more robust for emergent metastases than conventional imaging modalities such as magnetic resonance imaging (MRI) or computed tomography (CT). Next, we challenged our surveillance technology using a biomimetic model of metastatic breast cancer, which results in metastases at different anatomical Articles NaTuRe BIoMedIcal eNgINeeRINg sites and also shows dichotomous molecular profiles at these sites 18 . Figure 1 illustrates a non-invasive surveillance system that provides an integrated imaging system to track multi-organ metastases for xenogeneic and potential patient-derived models of cancer. This approach integrates distinct SWIR-emitting nanoparticles each designed to penetrate different metastatic organs and to enable longitudinal tracking of lesion development. The use of this surveillance system in the clinic will lead to major advances in altering and tailoring patient-specific niche-based therapeutic regimen.
Results
Design and characterization of C-X-C chemokine receptor type 4 (CXCR4)-targeted photonic nanoparticles. The dopant− host chemistries and heterostructure of rare-earth-doped nanoparticles govern their optical emission wavelengths and efficiencies 16, 20 , which have been optimized in our previous work 15, 17 . Rare-earth nanoparticles synthesized via a burst nucleation reaction 20, 21 were incorporated into ReANCs via solvent-induced controlled coacervation of albumin 22 (Supplementary Fig. 1a ). The sizes of the rare-earth nanoparticles (~18-25 nm diameter) and ReANCs (85-100 nm diameter) were tailored by controlling the reaction chemistry and kinetics to allow for the size-dependent enhanced permeation and retention (EPR) effect (at approximately below 100 nm) to permit passive targeting 11 . ReANCs were also engineered to actively target tissues such as the adrenal glands where the microcirculation prevents passive uptake. Briefly, functionalized ReANCs (fReANCs) were generated by decorating the surface of ReANCs with AMD-3100, a small molecule antagonist of the chemokine receptor and cancer biomarker CXCR4 23, 24 . AMD-3100 was adsorbed onto the surface of ReANCs to use native drug binding pockets on human serum albumin 25, 26 . Dynamic light scattering (DLS) analysis revealed monodisperse populations and minimal change in the hydrodynamic diameter of fReANCs compared with ReANCs ( Supplementary Fig. 1b ). Nanoparticle yield was quantified as approximately 58% using the bicinchoninic acid assay (BCA) protein assay. AMD-3100 loading efficiency was determined to be 70% by high-performance liquid chromatography, consistent with our previous study 19 . The fReANCs demonstrated active targeting as validated by competitive CXCR4 blockage and inhibition of cancer cellular migration assays ( Supplementary Figs. 2 and 3 ). Both native and functionalized ReANC formulations have exhibited no overt toxicity 15, 19 , which is consistent with our findings of no or little change in body weight (data not shown). Histopathology of major organs of clearance, such as liver, lung, kidney and spleen, extracted at various time points post-nanoparticle injection showed no abnormalities in tissue architecture ( Supplementary Fig. 4 ). In addition, normal histopathology from the organs of accumulation, such as the liver and lungs, following repeated weekly administration of nanoparticles ( Supplementary Fig. 5 ) indicated no signs of nanoparticle toxicity. Liver, lungs and spleen seem to be major organs of accumulation based on yttrium content per gram of tissue correlated with the content in the injected dose, as determined by inductively coupled plasma-mass spectrometry (ICP/MS) ( Supplementary Fig. 6a ). The clearance pattern of ReANCs from animals, determined using ICP/ MS, showed a decrease in nanoparticle content from all organs over the course of seven days. Accumulation in the spleen increased until day three, after which the nanoparticle content began to decline, indicating clearance ( Supplementary Fig. 6b ). The ICP/MS data showed correlation with the ex vivo SWIR signal from these respective organs ( Supplementary Fig. 6c,d ).
SWIR imaging of photonic nanoparticles discerns bone lesions in vivo that are undetectable by MRI and CT.
Detection of micrometastatic lesions in the bone marrow is challenging due to a lack of sensitive imaging modalities 27 . Current approaches can successfully detect abnormal bone activity, but are unable to identify cancer-related activity associated with bone metastases. Thus, there is a need for targeted imaging agents that enable sensitive imaging of the earliest metastatic cell clusters at otherwise inaccessible metastatic niches.
Female athymic nude mice were injected with bone-tropic MDA-MB-231-derived sterol carrier protein 2 (SCP2) cells in the intratibial cavity ( Fig. 2a ). Animals received weekly injections of unfunctionalized ReANC probes, beginning a week after tumour cell inoculation and were monitored using a preclinical SWIR imaging system (Fig. 2b,c) 15 . Longitudinal imaging showed greater than twofold higher SWIR fluorescence in tumour-bearing animals compared with healthy controls, from five weeks post-inoculation a, Distinct nanoparticles were designed with rare-earth-doped cores for different tissue microenvironments to enable whole-body screening based on deeper tissue-emanating short-wave infrared emissions. b, When administered in vivo to biomimetic breast cancer models, these nanoparticles are targeted to reach multi-organ metastatic sites across different pharmacologic barriers. c, Metastatic lesions (in the long bones or adrenal glands) can be detected earlier than with conventional methods (bioluminescence, MRI, CT) and molecular changes in cancer cell signatures can be obtained, forming the basis for future metastatic-site-specific, personalized cancer therapies.
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until the study endpoint ( Fig. 2d ). SWIR-imaging-based detection of tumours in the tibial cavity was validated by whole-body bioluminescence imaging (BLI) ( Fig. 2e ). Ex vivo SWIR imaging of the skeletons at the endpoint confirmed accumulation of ReANC probes in the bone space ( Supplementary Fig. 7 ). Notably, tumour lesions were barely discernible using common preclinical imaging 
modalities such as CT and MRI ( Fig. 2f,g) , even at the study endpoint. In addition, ex vivo hematoxylin and eosin (H&E) staining of tumour-bearing bone showed hypocellularization when compared with healthy controls, indicative of tumour-cell-mediated lytic activity in the bone (Fig. 2h ).
Distal bone lesions can be detected with SWIR imaging earlier than MRI in a biomimetic basal-like breast cancer metastasis model.
Having successfully imaged small clusters of tumour cells in a localized intratibial model, we examined the ability of wholebody SWIR imaging to discern metastatic lesions in a breast cancer bone metastasis model. We established a MDA-MB-231 model previously shown by Minn et al. to follow different seeding kinetics and to colonize the lungs and bones following intravenous administration 18, 28 . This model exhibits low metastatic burden in the bones and hind legs in contrast with a relatively high burden in the lungs 28, 29 . We inoculated female athymic nude mice with MDA-MB-231derived SCP28 cells via the tail vein, followed by weekly injection of ReANCs for SWIR imaging ( Fig. 3a and Supplementary Video 1). Compared with healthy controls (Fig. 3b ), tumour-bearing animals ( Fig. 3c ) revealed a greater than twofold increase in SWIR signal from the long bones, beginning at week five post-inoculation ( Fig. 3d ). Most significantly, by week nine, we observed a greater than fivefold increase in SWIR signal from the bones of tumourbearing animals compared with controls ( Fig. 3d ), while MRI still showed no abnormalities in the bone space ( Fig. 3e ) and BLI showed absence of tumour burden in the bone (Fig. 3f ). Nanoparticles encounter the lungs as their first barrier organ when administered intravenously, making the architecture of the lung vasculature an important determinant in their subsequent biodistribution to distant sites. A possible hypothesis for increased accumulation of ReANCs in the bone in this biomimetic model ( Fig. 3 ) compared with the previous intratibial model ( Fig. 2 ) could be that an altered vascular architecture due to tumour lesions in the lung is responsible for differences in nanoparticle biodistribution 30 . MRI analysis also revealed moderate tumour burden in the lungs (31.3 ± 25.4 mm 3 ; mean ± s.d.). Previous studies have shown passive uptake of ReANCs in the lungs only when the lesions are large and highly vascularized 19 . During the studies reported here, no discernible SWIR signal from the lungs was detected ( Fig. 3c,d ). This lack of lung signal reinforces the need to engineer nanoparticles for targeted uptake to organs such as lungs and adrenal glands where the infiltration barrier prevents passive uptake 12 .
Differential niche-based accumulation of ReANC and fReANC formulations leads to multi-organ detection of metastases in a luminal breast cancer model. While bone physiology favours the uptake of nanoparticles such as ReANCs ( Figs. 2 and 3 ), other tissues require active targeting to facilitate nanoparticle labelling. In addition, cancer patients with metastases at multiple sites frequently have a lower quality of life and poorer prognosis than those with a single distant lesion 31 . Therefore, it is imperative that metastasis imaging agents be designed to label phenotypically distinct lesions at physiologically distinct sites. To this end, we hypothesized that fRe-ANCs targeting the CXCR4 biomarker and non-targeted ReANCs could provide differential labelling of lesions at distinct organ sites in a biomimetic model of breast cancer metastasis.
The MCF-7-derived human metastatic breast cancer line was shown to express CXCR4 ( Supplementary Fig. 8 ). Athymic nude mice received intracardiac injections of MCF-7 cells to the left ventricle ( Fig. 4a ). This model of luminal breast cancer is known to phenocopy human disease, leading to both adrenal and bone metastases in mice supplemented with oestrogen 7 . Animals were given weekly injections of either fReANCs targeted to CXCR4 or non-targeted ReANCs, followed by SWIR imaging in both supine and dorsal positions. fReANCs preferentially accumulated in adrenal tumours ( Fig. 4b,d ), exemplified by an almost 15-fold increase in SWIR intensity at this site in tumour-bearing animals compared with healthy controls, even as early as three weeks postinoculation ( Fig. 4b-d ). Notably, there was no significant difference between SWIR signal intensity in tumour-bearing versus healthy control animals when unfunctionalized ReANC's were used ( Fig. 4b ,c,e). In contrast, we observed a fourfold increase in SWIR signal from the bones of tumour-bearing animals compared with healthy controls (Fig. 5a,b ) when unfunctionalized ReANCs were administered for imaging. In this case, the SWIR signal from the bones of animals receiving fReANCs was not elevated compared with healthy controls (Fig. 5b) .
The progression and location of metastases was monitored with bi-monthly MRI and validated by in situ and ex vivo SWIR imaging ( Supplementary Figs. 9 and 10 ). The smallest adrenal tumours detected by SWIR imaging were 7.8 mm 3 in volume following fRe-ANC administration and 15.7 mm 3 with ReANCs, confirming the ability of fReANCs to target and resolve smaller metastatic clusters when compared with untargeted ReANCs. Fixed tissue sections were stained for oestrogen receptor and confirmed the presence of tumours in the adrenal glands (Supplementary Figs. 11 and 12).
While we were able to demonstrate differential accumulation of the nanoprobes in distinct metastatic organ sites, another goal of this nanotechnology system is to enable surveillance of multi-organ metastases within the same animal. To this end, we injected a cocktail of untargeted and targeted nanoprobes in a triple negative metastatic breast cancer mouse model. The MDA-MB-231 metastatic xenograft model led to lung and bone metastases when cells were inoculated intravenously into the animal followed by injection of a cocktail of ReANCs and fReANCs ( Fig. 6a ). We were able to reproduce enhanced localization of targeted nanoprobes to lungs ( Fig. 6b ) and untargeted probes to leg lesions ( Fig. 6c ) as evidenced by a statistically significantly higher SWIR signal in tumour-bearing animals compared with healthy controls. In a pilot study, we observed qualitative evidence of preferential accumulation of ReANCs ( Fig. 6d ) in the leg and fReANCs in the lungs (Fig. 6e ). Notably, we demonstrate accumulation in both lungs and legs when a cocktail of ReANCs and fReANCs were co-administered ( Fig. 6f,g) . Future studies will work on dose optimization and mechanistic insights for active and passive targeting of the nanoprobes in the same animal.
Superior resolution with SWIR imaging compared with contrast-enhanced MRI for bone lesion detection in a biomimetic
mouse metastatic model. SWIR imaging using ReANCs could detect bone lesions in orthotopic and metastatic models of breast cancer. We demonstrated that these bone lesions were undetectable by conventional MRI. However, to make a direct quantitative comparison to assess superior resolution with SWIR emitting nanoprobes, we performed contrast-enhanced MRI (CE-MRI) studies in an experimental metastatic triple negative breast cancer model with metastases to both lungs and bone. We proposed to use detection of lung lesions pre-and post-contrast as positive control for CE-MRI. We injected ReANCs bi-weekly to monitor SWIR signal in bones of animals. Bi-weekly MRI using contrast was performed in parallel for comparison.
In particular, we are able to detect bone lesions at week six postinoculation of tumour cells, as evidenced by a statistically significant, twofold increase in SWIR emission compared with non-tumour control animals. We also demonstrate that these lesions were not detectable by CE-MRI at week six ( Fig. 7a,b ) and that the apparent increase in MRI signal is not statistically significant until week eight ( Fig. 7d ). Most notably, SWIR emission in tumour-bearing animals was visualized two weeks before and with far greater fold increase in signal than CE-MRI ( Fig. 7c ). Quantitative changes with CE-MRI between non-tumour controls and tumour-bearing animals were not statistically significant at week six. In addition, as a control for NaTuRe BIoMedIcal eNgINeeRINg contrast enhancement, we quantified MRI-contrast intensity in kidneys and found no significant change between tumour-bearing and non-tumour controls ( Supplementary Fig. 13 ). Contrast enhancement of lung lesions was used as positive control (Fig. 7e,f ).
Distinct metastatic lesions originating from a common cell line exhibit niche-dependent molecular signatures.
As the metastatic microenvironment of each pre-metastatic niche can cause site-specific variations in protein signatures, the ability for imaging agents to parse such site-specific molecular profiles will have far-reaching preclinical and clinical impact in developing diagnostic tools and therapeutic interventions in recurrent cancers. To further elucidate the role of the metastatic niche on the phenotypic signatures of metastatic lesions, cells were harvested from bones (MCF-7-5624a and SCP28), adrenal glands (MCF-7-6124A) and lungs (SCP28) in the metastatic tumour models ( Supplementary Fig. 14a ). Cell lysates extracted from these were analysed for differences in protein expression. In the luminal breast cancer model, analysis of microarray pixel density revealed upregulation of N-cadherin, ADAM17 (ADAM metallopeptidase domain 17) and JAM-A (junctional adhesion molecule-A) in adrenal-tropic cells ( Supplementary Fig. 14b ), while bone-tropic cells were found to upregulate a separate set of markers, including Notch-1, amphiregulin and EGFR (epidermal growth factor receptor) ( Table 1) .
Bone-tropic 5624a cells expressed a twofold increase in Notch-1 relative to adrenal-tropic cells. Notch-1 upregulation has previously 
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been correlated with bone metastases and the presence of lytic lesions 32 , while N-cadherin is associated with tumour invasiveness, growth and metastasis 33 . Adrenal-tropic cells exhibited a 4.75-fold increase in N-cadherin expression compared with bone-tropic cells, suggestive of a more aggressive tumour phenotype.
In the triple negative breast cancer model (SCP28), we found niche-based differences in protein expression in the lung-tropic and bone-tropic lines using a human oncology array. We found in the lung-tropic line upregulation of metastasis-associated proteins such as amphiregulin, endoglin and carbonic anhydrase-IX ( Supplementary Fig. 14c ). Interestingly, the bone-tropic cells showed upregulation of two of the proteins present in the lung niche-signature namely amphiregulin and endoglin. In addition, we found an increase in MMP-3 (matrix metalloproteinase-3) and EpCAM (epithelial cell adhesion molecule) in the bone niche ( Supplementary Fig. 14d ). The significant differences observed in molecular signatures between cell populations at various metastatic sites correlate with our ability to target these two metastatic lesions using divergent design criteria for our SWIR-emitting nanoparticles. These distinct molecular signatures also exemplify potential targets to develop niche-specific targeted nanoparticles for imaging and therapy.
Discussion
Cancer metastasis is a process whose dynamics remain poorly understood due to the limited ability of existing techniques to obtain meaningful information in real time. Optical imaging of metastasis in live animals under native physiological conditions has been innately difficult due to poor tissue penetration and high background levels due to tissue autofluorescence. Most preclinical imaging in multi-organ metastatic models has been invasive, using intravital imaging windows and genetically engineered cells that express luciferase or fluorescent reporters [34] [35] [36] [37] . The goal of this work was to develop an optical imaging system that could resolve multiorgan lesions at distant metastatic sites in real time without necessitating genetically altered reporter cells.
We demonstrated that appropriately sized rare-earth albumin nanocomposites are able to home to micro-metastatic lesions in the long bones (Figs. 2, 3 and 5) and spine (represented in Supplementary Video 1) in multiple in vivo breast cancer models. Because of robust nanocomposite accumulation and deep-tissue imaging SWIR emissions, micro-metastatic lesions were observed as early as three weeks post-inoculation in an orthotopic model of breast cancer. We demonstrated that weekly injection of ReANCs showed consistent, rapid accumulation in the bones with complete 
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clearance by 48 h post-injection ( Supplementary Fig. 7) , rendering the nanoprobes safe for repeated use in longitudinal studies. Notably, the ReANC probes elicited no overt toxicity when compared with controls ( Supplementary Figs. 4 and 5 ) and control animals showed no signs of distress during the study period. The clearance of ReANCs through major organs of clearance was within acceptable limits up to seven days post-administration of probes ( Supplementary Fig. 6 ). Remarkably, MRI and CT did not reveal any changes in bone architecture. Histopathology also validated regions of possible changes in bone architecture when compared Articles NaTuRe BIoMedIcal eNgINeeRINg with tissue sections from control animals. Most notably, CE-MRI did not show significant quantitative changes at week six, when bone lesions detected by SWIR imaging were significant between tumour-bearing versus control animals (Fig. 7) .
In a biomimetic model where multi-organ metastases to the lung and bone are observed, we found differential accumulation of ReANCs to lesions in the bone as early as three weeks postinoculation. This was consistent with our previous findings, where ReANCs could not discern lung metastases until lesion volume reached around 56 mm 3 (ref. 19 ). Bone lesions were undetectable on MRI and BLI whereas lung lesions were detected by MRI and BLI. Differential uptake of nanoparticles based on size 15, 38 and surface functionalization 38 has been demonstrated in previous in vitro and in vivo studies. An added benefit of the differential nanoparticle uptake, especially via active targeting, is that we can quickly reduce the percentage of particles remaining in systemic circulation therefore achieving further reduction in unwanted background signal. Of particular interest in metastasis imaging would be a nanoparticle formulation that can be modified and administered systemically to detect distal multi-organ metastases in real time. Simultaneous detection of metastases at multiple distinct sites is important for effective treatment as undetected lesions lead to recurrent disease. These persistent tumours are often resistant to therapy and require lesion-specific intervention 39 . The ability to detect phenotypically distinct tumours at distant sites is critical in predicting the likelihood of recurrence and in selection of effective therapies 28, 29 .
Intrinsic to the nanoprobe detection of multi-organ metastases is the design of multivariate targeting mechanisms. For the ReANC Week 6
Week 6
Week 8
Week 8 Cancerous cells isolated from adrenal glands and bones were cultured ex vivo and analysed for changes in biomarker expression with a hematopoietic array. Cellular markers upregulated in adrenal-tropic lines were typically associated with increased tumour growth and invasion, while those upregulated in the bone-tropic line act to promote bone resorption. ERK, extracellular signal regulated kinase; MEK, mitogen activated protein kinase kinase; TGFα , transforming growth factor alpha; Rap1 GTPase; Ras-activated protein 1 guanine triphosphate; TGFβ , transforming growth factor beta; SMAD, mothers against decapentaplegic homolog; RANKL, receptor activator of nuclear kappa-B ligand.
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nanoprobes to penetrate through barriers in organs such as lungs, the design strategy would call for the display of a surface charge (to undergo transcytosis) or a targeting ligand (especially for chargeneutral particles such as human serum albumin-coated probes) to exhibit receptor mediated-endocytosis 40 . Other reports highlight the role of size, charge, shape and targeting ligand selection in altering nanoparticle infiltration through various barriers leading to the tumour in an animal model 41, 42 . In our study, a combination of passive and active targeting may be key to the detection of tumours in the bones and adrenal glands, respectively. Sinusoid capillary fenestrations play a major role in nanoparticle delivery and, in combination with leaky vasculature of tumours, this could play a role in the increased accumulation of unfunctionalized ReANCs in the bone. In addition, the changes in bone architecture associated with tumour progression may also play a role in improved accumulation of ReANCs in the bone. In contrast, the adrenal glands showed poor accumulation of unfunctionalized ReANCs along with pronounced recruitment of the functionalized fReANCs, which indicates the role of active targeting. The active targeting of our functionalized fRe-ANCs is designed based on elevated CXCR4 binding (validation in Supplementary Figs. 2 and 3 ). Tumour-targeted fReANCs were able to resolve adrenal lesions as small as 8 mm 3 and detect these lesions earlier than ReANCs, suggesting that the continuous fenestration of capillaries around adrenal tissue is not amenable for EPR of ReANCs. This result, combined with our previous studies in a lung metastasis model, indicates that ReANCs require a certain tumour burden in certain niches for accumulation, whereas sites such as the bone permit uptake with a relatively low tumour burden. To explore the relevance of our probes to a different metastatic model, we tested accumulation of fReANCs on intravenous inoculation of MDA-MB-231 cells. Here, we demonstrated using a pilot study that the probes can effectively resolve a different profile of multi-organ metastases (actively targeted fReANCs bound to metastases in the lungs versus passively targeted ReANCs accumulated in the bone) ( Fig. 6 ). Future studies could exploit these differences to explore the use of our imaging tools to further track nanoparticle penetration through the vascular, perivascular and interstitial space in tumours.
Understanding the molecular basis of interactions between a primary tumour, distant metastases and the metastatic niche is critical to fulfil the promise of improved and personalized therapies in cancer patients. Our study highlights an integrated approach for the sensitive and accurate detection and analysis of micro-metastatic lesions. Proteomic analysis of cells isolated from metastatic sites highlighted by distinct classes of the nanoprobes showed a clear dichotomy in molecular signatures. Specifically, increased Notch-1 in bone lesions vis-à-vis N-cadherin in adrenal-gland metastases provides molecular context to the metastatic process that can potentially be exploited for tailoring precision therapeutics to individual patients. Notably, early detection of lesions facilitated extraction and analysis of changes in niche-based signatures from tumour onset to endpoint. Collectively, these outcomes suggest that our system can longitudinally perform non-invasive molecular assessment of metastases and also monitor treatment outcomes targeted to highly heterogeneous metastatic lesions 29, 43 .
In summary, we have developed an integrated multi-organ-metastasis imaging system for the detection and analysis of early metastatic lesions in distal organs. We demonstrated the applicability of this imaging system in several distinct in vivo breast cancer models. Future preclinical applications of this approach will expand on the customization of ReANC probes with markers specific for metastatic lesions, based on the niche surrounding these clusters. Researchers could design a cocktail of such site-interactive ReANC formulations to detect, track and understand interactions between cells in these different compartments, providing clues that will eventually lead to the development of better therapeutic agents for the clinic. As a whole-body surveillance system, we envision this to be a scanning imaging tool for pre-and post-therapy monitoring in preclinical settings, via real-time noninvasive molecular detection of lesions in multiple organs.
Methods
Fabrication of rare-earth nanoparticles. Rare-earth nanoparticles were synthesized as previously described via burst nucleation reaction 15, 20, 21 , and incorporated into ReANCs via solvent-induced controlled coacervation of albumin 15, 22 . Hydrodynamic diameters of ReANCs were determined via DLS (Malvern Instruments) ( Supplementary Fig. 1a ), which also revealed monodisperse particle populations. Two classes of ReANCs were designed for targeting distinct classes of metastatic sites. Albumin-based ReANCs were administered as unfunctionalized composites for detection of bone cancer metastases. In contrast, fReANCs were designed for targeting of adrenal-gland metastases. fREANCs were generated through passive absorption of the CXCR4-antagonist AMD-3100 (EMD Millipore) onto the surface of fully formed ReANCs. A range of AMD-3100 concentrations from 12.5 μ M to 12.5 nM were generated for in vitro testing to determine the optimal loading conditions 19 . An AMD-3100 loading concentration of 1.25 μ M was found to be optimal based on our in vitro testing, and was used for all in vivo experiments. Nanoprobe diameter and polydispersity were determined through DLS; nanoprobe yield was determined by BCA protein assay.
In vivo imaging. Imaging studies were conducted using athymic nude female homozygous nude mice 15, 19 (Taconic). Whole-body BLI was performed using an MsFxPRO system (Carestream Molecular Imaging). Anaesthetised animals were injected with D-luciferin (Perkin-Elmer) and imaged 10 min post-administration to obtain a significant signal. All animal studies were approved by the Institutional Review Board for the Animal Care and Facilities Committee of Rutgers University and performed in accordance with institutional guidelines on animal handling.
Whole-animal SWIR imaging.
A small animal SWIR imaging system was assembled in-house 15, 19 . Mice were fully anaesthetised using 2% isoflurane (Butler-Schein) and were continuously scanned with a collimated 980 nm laser (1.7 W). SWIR emission was detected with an InGaAs camera (Sensors Unlimited) equipped with two 1,020 nm long-pass filters and a band-pass 1538/82 nm filter (Semrock) and a 25 mm focal length SWIR lens (StingRay Optics). The system is capable of real-time animal imaging with an exposure time of 33 ms per frame. Images were acquired as video files and processed for quantitative analysis using custom Matlab scripts, as described in 'SWIR image analysis' . Animals injected with 200 μ l of ReANCs intravenously were imaged at 20 fps and a representative video postprocessed to show localization of particles is shown in Supplementary Video 1.
MRI and CT imaging. MRI images were acquired using 1 Tesla M2 highperformance MRI system (Aspect Magnet Technologies). CT images were acquired using ALBIRA PET/CT system (Carestream Molecular Imaging). All imaging procedures were performed under inhalation anaesthesia with isoflurane at a concentration of 4% for induction of anaesthesia and 1-2% for maintenance. Volumetric three-dimensional reconstruction to determine tumour volumes was performed using Vivoquant software (Aspect Magnet Technologies). For CE-MRI, pre-contrast fast spin echo and gradient echo images were acquired followed by injection of Magnevist (gadopentetic acid; Henry Schein) and acquisition of postcontrast gradient echo and fast spin echo images. Analysis of T 1 and T 2 weighted images were performed as described under MRI image analysis.
Cell lines. The cell lines used in this study were obtained from the following sources: SCP2 and SCP28, animal-derived, provided by Y. Kang; MCF7-5624a, animal-derived, provided by V.G.; MDA-MB-231 and MCF7 (ATCC). The authenticity of the animal-derived lines to the parental lines was tested using cellline authentication services utilizing short tandem repeat (STR) profiling (ATCC, VA). Animal-derived cell lines have not been tested for mycoplasma contamination on procurement but were tested for mycoplasma by using PCR detection methods.
Orthotopic model of bone metastasis.
Bone-tropic MDA-MB-231-derived SCP2 cells expressing luciferase 18 (a gift from Dr Kang, Princeton University) were maintained in Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. 1 × 10 5 MDA-MB-231-derived SCP2 basal-like breast cancer cells were injected into the tibiae of 3-4-week-old female homozygous athymic nude mice under inhalation anaesthesia with 2-3% isothesia 7 . Whole-body SWIR imaging was performed on all animals both pre-and post-ReANC injection (200 μ l; 10 mg kg −1 ; intravenous administration via tail vein). Tumour progression was monitored longitudinally by using SWIR imaging weekly over a ten-week time course. SWIR intensity from the tibia of tumour-bearing and healthy control animals was quantified to determine the accumulation of ReANCs. The presence of tumour in the bone space was confirmed using BLI at week nine. MRI was used to monitor any bone deformities due to the presence of lytic lesions.
Biomimetic model of bone metastasis.
Parental MDA-MB-231-and MDA-MB-231-derived SCP28 cells 18 (a gift from Y. Kang, Princeton University) were maintained in DMEM supplemented with 10% fetal bovine serum and 1% NaTuRe BIoMedIcal eNgINeeRINg penicillin/streptomycin. Three-to-four-week-old homozygous female athymic nude mice were intravenously inoculated via the tail vein with the MDA-MB-231-derived SCP28 breast cancer cell line (2 × 10 5 cells; a gift from Y. Kang, Princeton University; note that SCP28 are a subclonal population different from SCP2), leading to the development of lung and bone lesions 18 . Animals received weekly injections of ReANCs (200 µ l, 10 mg kg −1 , via intravenous administration) to detect and monitor tumour progression over a ten-week time course. In another study, MDA-MB-231 cells (3 × 10 5 cells) were injected intravenously into 4-5-week-old female athymic nude mice. Animals received weekly injections of ReANCs, fReANCs or a cocktail of ReANCs and fReANCs (200 µ l, 10 mg kg −1 , via intravenous administration) to detect and monitor tumour progression over a ten-week time course. Whole-body SWIR imaging was performed pre-and post-ReANC administration. Tumour burden was validated by bi-monthly MRI. CE-MRI was also performed to determine tumour burden in legs.
Biomimetic model of multi-organ distal metastases. Bone-derived MCF-7-5624A cells were maintained in DMEM supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin 7 . The authenticity of the animal-derived line to the parental line was tested using the cell line authentication services using short tandem repeat profiling (ATCC). MCF-7-5624A tumour cells were injected into the left cardiac ventricle (5 × 10 5 cells) in 3-4-week-old homozygous female athymic nude mice (Taconic) supplemented with low-dose oestrogen pellets (0.18 mg; Innovative Research of America) that deliver 2 μ g d −1 of 17β estradiol. Tumour progression and size was monitored through BLI and MRI. Mice received weekly injections of ReANCs or fReANCs functionalized with 12.5 μ M AMD-3100 at 10 mg kg −1 body weight and were imaged immediately post-injection and up to 24 h post-administration. SWIR signal from the leg bones and the dorsal area corresponding to the location of the adrenal glands was quantified. Animals were killed on weight loss and organs were excised. Tumour volume was calculated using three-dimensional reconstructions generated from MRI imaging.
Ex vivo analysis of bone microlesions. At experimental endpoints, animals
were euthanized and bones were excised and fixed in formalin. Bones were later decalcified in 0.5 M EDTA for 24-48 h and stored at 4 °C in 70% ethanol before processing. Tissues were then embedded in paraffin and 5 μ m sections prepared. Tissue sections were de-paraffinized, rehydrated and stained with H&E before mounting and imaging under standard light microscopy (Nikon).
Ex vivo analysis of adrenal lesions.
Adrenal tumours were removed, fixed in 10% neutral-buffered formalin overnight and stored at 4 °C in 70% ethanol before processing. Tissues were then embedded in paraffin and 5 μ m sections prepared. Tissue sections were de-paraffinized, rehydrated and stained with H&E, as well as with rabbit monoclonal anti-human ERα IgG (catalogue no: ab16660, Clone SP1, Spring Bioscience) and rabbit monoclonal anti-human CXCR4 IgG antibody (catalogue no: ab181020, Clone EPUMBR3, Abcam). Control slides were stained using appropriate isotype control antibodies. Biotinylated secondary antibodies were used for detection. SWIR image analysis. SWIR emission from animals was collected pre-and postinjection of nanoparticles in the form of a video file in .bin format. A white light image of the animal for both time points was taken and labelled according to the condition. The bin file-converting Matlab file was used to process the video files to extract maximum pixel values from each frame of the video and saved as a tiff image file. Image processing was done through manual selection of regions of interest (ROI). ROIs corresponding to the desired organ were selected using anatomical landmarks present in background images. These ROIs were then applied to the associated infrared image, and the mean SWIR signal intensity over space for the region of interest was calculated. These values were then used to perform statistical analyses to compare the SWIR signal from each ROI between tumour-bearing and healthy control groups.
MRI image analysis.
Post-contrast changes in signal intensity were quantified by exporting the images acquired using T2 MRI as dicom files and analysing them using vivoquant software. Unique image scale factor for each image is extracted and applied to the individual image before quantification for normalization. Post-normalization, the bone space of the animal is selected using the threedimensional ROI tool in vivoquant. The mean pixel intensity value in the selected three-dimensional space is generated as an Excel file by the software. The increase in pixel intensity due to contrast injection is evaluated by analysing both pre-and post-contrast MRI scans. The increase of pixel intensity was compared between the tumour-bearing and healthy control animal groups.
Human soluble receptor array and human oncology array for molecular phenotyping. Organs bearing metastatic tumours were processed and the resulting cells collected and cultured. To isolate tumour cells from bone lesions, a 1 ml syringe with a 26 G needle was filled with phosphate buffered saline and inserted into one end of the tibia and cells expelled from the other end by applying positive pressure to the syringe. For adrenal and lung tumours, cells were crushed and homogenised using frosted glass slides and cells filtered to remove debris using a cell strainer (Falcon). After one to two weeks of culture, a pure population of human cancer cells was obtained. Cell line protein expression was evaluated using with the Human Soluble Receptor Array Kit Non-Hematopoietic Panel or Human Oncology Array (R&D systems) according to the manufacturer's instructions. Array results were quantified in terms of pixel density using ImageJ (National Institues of Health) and the degree of fold change was determined by comparison with that of the parental line.
Quantitative biodistribution, clearance and toxicology studies. Athymic nude mice were injected with 10 mg kg −1 of ReANCs. Primary organs of clearance (liver, lung, kidney and spleen) were harvested at 0 h, 1 d, 3 d and 7 d post-injection and imaged ex vivo using the SWIR imaging system. Ex vivo SWIR intensity was correlated to nanoparticle (yttrium) content in organs as determined by ICP-MS. Briefly, yttrium content of digested organs taken from mice was quantified using a Thermo X series II ICP-MS (Thermo Scientific) to determine particle concentration after injection. All samples were digested in 16 M nitric acid (Fisher Scientific) and evaporated to dryness, then reconstituted in 10% nitric acid to account for differences in sample volume. Count rates for yttrium were correlated to parts per billion using a standard curve generated with an yttrium standard (Sigma-Aldrich). Percentage of injected dose was calculated by correlating yttrium content in the injected nanoparticle dose to yttrium content per gram of tissue.
Competitive inhibition of CXCR4 as a measure of passive targeting. MDA-MB-231 cells were cultured in DMEM (Gibco, Thermo Fisher Scientific) supplemented with 10% FBS and 1% penicillin-streptomycin. Cells were plated in a 96 well plate (Falcon, Corning Brand) at a cell density of 100,000 cells per well. The ligand stromal cell-derived factor-1α (PeproTech) was added to cells at concentrations of 10 nM and 100 nM, and incubated at 37 °C for 2 h. Following this, cells were treated with ReANC and fReANCs and incubated at 37 °C for 15-18 h. Cells were fixed in 1% paraformaldehyde subsequent to trypsinization and washes. The samples were then analysed via fluorescence-assisted cell sorting (FACSCaliber, BD Biosciences) and uptake quantified as a function of green fluorescence from the albumin shell. Data were analysed using Kaluza Analysis software (Beckman Coulter).
In vitro optimization of nanoprobes. Scratch and cell migration assays were used to determine the effect of AMD-3100 functionalization on cell mobility. In the scratch assay, MCF-7 cells were plated in six-well plates and allowed to grow until confluent. These cell monolayers were scored with a pipette tip and samples were treated with varying concentrations of ReANCs, fReANCs and free AMD-3100 in solution. The scratches were imaged over the course of 24 h to measure wound closure and cellular movement into the scratch. Cell migration was evaluated by measuring cell movement through 8 μ M transwell inserts. MDA-MB-231 cells were plated on top of 8 μ M transwell inserts and treated with ReANCs, fReANCs and free AMD-3100 in solution. Cells were then allowed to migrate through the mesh. Cell migration was evaluated through microscopy and crystal violet staining.
Statistical analysis.
For all in vivo studies, animal number was determined using G-power analysis (analysis of variance, one-way, omnibus) providing at least 70-80% power and an effect size of 0.8-0.85, with α set at 0.05. Full experimental details are provided in the Methods section(s) above, to ensure independent reproducibility by other investigators. For all in vivo studies, mice were randomly assigned to each experimental or control group and investigators were not blinded to the groups through the process of acquiring and analysis of data. Grubb's test for outliers was used to determine the inclusion or exclusion of data within groups for all datasets. The similarity of the variance between the groups was tested using the F-test of equality of variances using a confidence interval of 95%. Statistical tests were selected based on the normality of the distribution, sample size and the similarity in variance between groups. Statistical significance of the normal populations and was determined using a two-tailed Student's t-test or Welch's t-test. All statistical analysis was done using graphpad prism version 7.0 (GraphPad Software; www.graphpad.com).
Life Sciences Reporting Summary. Further information on experimental design is available in the Life Sciences Reporting Summary.
Code availability. Three MATLAB image-processing scripts are available on Github (https://github.com/markpierce50/Nature-BME-2017/releases/latest).
Data availability.
The data that support the findings of this study are available within the paper and its supplementary information. Corresponding author(s): Prabhas V. Moghe,PhD., Vidya Ganapathy,PhD., Mark C. Pierce, PhD.
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Experimental design 1. Sample size
Describe how sample size was determined. For all in vivo studies, animal number was determined by using G-power analysis (ANOVA, one-way, omnibus), providing at least 70-80% power and an effect size of 0.8-0.85, with α set at 0.05.
Data exclusions
Describe any data exclusions. Grubb's test for outliers was used to determine the inclusion or exclusion of data within groups of all data sets.
Replication
Describe whether the experimental findings were reliably reproduced.
For in vivo experiments no variability from animal to animal was observed, which indicates reproducibility of the data.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
For all in vivo studies, mice were randomly assigned to each experimental or control group.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Investigators were not blinded to the groups through the process of acquiring and analysis of the data, due to limited personnel.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
